2012
Discontinuation of Antihyperglycemic Therapy After Acute Myocardial Infarction: Medical Necessity or Medical Error?
Lovig KO, Horwitz L, Lipska K, Kosiborod M, Krumholz HM, Inzucchi SE. Discontinuation of Antihyperglycemic Therapy After Acute Myocardial Infarction: Medical Necessity or Medical Error? The Joint Commission Journal On Quality And Patient Safety 2012, 38: 403-407. PMID: 23002492, PMCID: PMC3534988, DOI: 10.1016/s1553-7250(12)38051-3.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionLeft ventricular ejection fractionAntihyperglycemic therapyDiabetic patientsMyocardial infarctionMedical necessityOne-year mortalityDetailed chart reviewVentricular ejection fractionIschemic heart diseaseNational Medicare databaseMedical errorsAcademic medical centerQuality improvement opportunitiesChart reviewClinical characteristicsOlder patientsRecurrent hypoglycemiaEjection fractionMedicare databaseBlood glucoseHeart diseasePrincipal diagnosisCommunity hospitalMedical Center
2010
Discontinuation of Antihyperglycemic Therapy and Clinical Outcomes After Acute Myocardial Infarction in Older Patients With Diabetes
Lipska KJ, Wang Y, Kosiborod M, Masoudi FA, Havranek EP, Krumholz HM, Inzucchi SE. Discontinuation of Antihyperglycemic Therapy and Clinical Outcomes After Acute Myocardial Infarction in Older Patients With Diabetes. Circulation Cardiovascular Quality And Outcomes 2010, 3: 236-242. PMID: 20354220, DOI: 10.1161/circoutcomes.109.887620.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionAntihyperglycemic therapyAntihyperglycemic agentsOlder patientsMyocardial infarctionMortality rateMultivariable Cox proportional hazards modelsCox proportional hazards modelFrequency of discontinuationGlucose-lowering agentsGlucose-lowering therapyInclusion/exclusion criteriaProportional hazards modelYear of dischargeHigh mortality rateDiabetic regimenFirst rehospitalizationReadmission ratesSecondary outcomesHeart failurePrimary outcomeClinical outcomesMultivariable analysisRetrospective studyIndependent association
2004
Management of implantable cardioverter defibrillators in end-of-life care.
Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Annals Of Internal Medicine 2004, 141: 835-8. PMID: 15583224, DOI: 10.7326/0003-4819-141-11-200412070-00006.Peer-Reviewed Original ResearchAdverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials
Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials. JAMA Internal Medicine 2004, 164: 1389-1394. PMID: 15249347, DOI: 10.1001/archinte.164.13.1389.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedBisoprololBradycardiaCarbazolesCarvedilolDizzinessFatigueFemaleFollow-Up StudiesHeart Conduction SystemHeart FailureHumansHypotensionMaleMetoprololMiddle AgedPropanolaminesRisk FactorsRisk Reduction BehaviorSeverity of Illness IndexStatistics as TopicTreatment FailureVentricular Dysfunction, LeftWithholding TreatmentConceptsBeta-blocker therapyHeart failureAdverse effectsLeft ventricular systolic dysfunctionBeta-blocker trialsCardiovascular adverse effectsChronic heart failureHeart Failure TrialVentricular systolic dysfunctionΒ-blocker therapyRisk of hypotensionLife-saving therapyRandom-effects modelHF hospitalizationCause mortalitySystolic dysfunctionCause withdrawalsFailure TrialRandomized trialsAbsolute riskElectronic searchPatientsMEDLINE databaseTherapyAbsolute increase